Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.


  1. Búsqueda avanzada de patentes
Número de publicaciónUS3729568 A
Tipo de publicaciónConcesión
Fecha de publicación24 Abr 1973
Fecha de presentación23 Sep 1969
Fecha de prioridad23 Sep 1969
También publicado comoCA945069A1, DE2046119A1, DE2046119C2
Número de publicaciónUS 3729568 A, US 3729568A, US-A-3729568, US3729568 A, US3729568A
InventoresKligman A
Cesionario originalJohnson & Johnson
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Acne treatment
US 3729568 A
Resumen  disponible en
Previous page
Next page
Reclamaciones  disponible en
Descripción  (El texto procesado por OCR puede contener errores)

April 24, 1973 A. M. KLIGMAN 3,729,568

ACNE TREATMENT Filed Sept. 23, 1969 5 Sheets-Sheet 1 INVE TOR JZBE/Ff M z/a ATTORNEYS April 24, 1973 A. M. KLIGMAN ACNE TREATMENT 3 Sheets-Sheet 2 Filed Sept. 23, 1969 FIG.

INVENTOR 4zamr/Mfl/aM/1/v ATTORN EYS April124, 1973 A. M. KLIGMAN 3,729,568

ACNE TREATMENT Filed Sept. 23, 1969 3 Sheets-Sheet 3 FIGA mv TOR "WM 414mm ATTORNEYS United States Patent 3,729,568 ACNE TREATMENT Albert M. Kligman, Philadelphia, Pa., assignor to Johnson & Johnson, New Brunswick, NJ.

Continuation-impart of application Ser. No. 678,493,

Oct. 25, 1967. This application Sept. 23, 1969, Ser.

Int. Cl. A611; 15/02 US. Cl. 424-318 Claims ABSTRACT OF THE DISCLOSURE The dermatologic disorder called acne vulgaris is controlled by topical application of vitamin A acid to the affected area. The application is made daily with a composition of low vitamin A acid content in the order of about 0.1%, by weight, until the acne is relieved. Particularly suitable compositions for topical applications are also provided.

This application is a continuation-in-part of application Ser. No. 678,493 filed Oct. 25, 1967 now abandoned.

BACKGROUND OF INVENTION Acne is a dermatological disorder which is more prevalent in adolescence and is found mainly within the age group of about to 22. As it occurs primarily in the face and trunk are'as, affecting the appearance of the patient, it probably causes more mental pain and anguish to those afiiicted than many other diseases which, from a physical standpoint, may be much more severe. The basic lesion of acne is the comedo or blackhead of a pilosebaceous follicle. The condition may be mild and transient with only a few blackheads which can readily be ejected by pressure and are of little concern, or may be severe, persistent, and very disfiguring with the more serious cases frequently leaving permanent scarring.

There have been many treatments proposed for acne, almost any treatment giving some relief. What appears to occur in the development of acne is that there is an initial filling up of the follicle with a rather tough, keratinous material. This impaction of horny material is the whitehead and blackhead. As a result of bacterial growth in these horny impactions, the follicle ruptures initiating the inflammatory phase of the disease which takes the form of pustules, papules, cysts and nodules.

One of the commonly used methods for acne treatment is the use of peeling agents which cause exfoliation with the removal of some of the keratinous plugs. In the more serious cases where pustular or cystic lesions exist, the same are evacuated by incision and the contents expressed. Various other therapies have been employed, such as vaccine therapy, to assist in the control of chronic infection and increase the patients resistance to Staphylococci; hormone therapy, which is applicable only for female patients who may be put on routine contraceptive regimen with estrogens; antibacterial therapy for the treatment of extensive pustular or cystic acne where the patient may be treated with tetracycline's, penicillin, erythromycin, or other of the antibacterial agents and, in some instances, general surgical skin planing may be used.

Although many different approaches have been used for the treatment of this almost universal afliiction, none of the heretofore topical treatments has been found to be particularly effective, although the systematic adminis tration of hormones and antibacterials has been shown to have some merit.

The administration of large oral doses of vitamin A has been suggested as being beneficial in acne, Straumford, J. V.: Vitamin A: Its Effects on Acne, Northwest Med., 42; 219-225, August 1943), although other investigators 3,729,568 Patented Apr. 24, 1973 have felt it to be ineffective (Anderson, J. A. D. et al., Vitamin A in Acne Vulgaris, Brit. Med. J., 2: 294-296, August 1963; Lynch, F. W. et al., Acne Vulgaris Treated With Vitamin A, Arch Derm., 55: 355, 357, March 1947, and Mitchell, G. H. et al., Results of Treatment of Acne Vulgaris by Intramuscular Injections of Vitamin A, Arch. Derm., 64: 428430, October 1951).

Vitamin A acid has been applied topically, Beer (Beer, Von P., Untersuchungen iiber die Wirkung der Vitamin A-Sure, Dermatologica, 124: 192-l95, March 1962) and Stiittgen (Stiittgen, G., Zur Lokalbehandlung von Keratosen mit Vitamin A-Saure, Dermatologica, 124: 6580, February 1962) achieving good results in those hyperkeratotic disorders which are responsive to high oral doses of vitamin A. Among those treated by Beer and Stiittgen were patients with acne; however, these investigators reported no eifective results on this disorder. British Patent 906,000 discloses a cosmetic preparation containing vitamin A acid for regulation of the cornification processes of human skin.

It has now been shown that acne vulgaris can be relieved and the skin cleared of comedones, and, in some cases, of the disfiguring pustules and cysts through the repeated daily application of vitamin A acid applied topically to the aifected areas. The application of the vitamin A acid results in an irritation, as shown by peeling and diffuse redness of the skin in the treated areas. The topical treatment with the vitamin A acid is continued until the acne is no longer apparent. If the irritation resulting from the treatment appears to be substantially subsiding while the acne is still present, the number of daily treatments may be increased and/or the concentration of vitamin A acid in the topical application may be increased. Normally, however, daily topical applications, one to two times each day, with the vitamin A acid at a fixed concentration in the applied composition, are entirely satisfactory.

I have discovered that acne vulgaris can be effectively cleared through the repeated topical application of vitamin A acid to the affected skin area when the vitamin A acid is applied over an extended period of time in such manner and such concentration as to cause noticeable irritation when applied. Vitamin A acid is used in the present specification and claims refers to a composition in which the terminal methylene group of vitamin A has been replaced by a carboxyl group. It is also known as retinoic acid.

The vitamin A acid is preferably applied in a liquid solvent. A composition found to be particularly effective is vitamin A acid dispersed in small amounts in a watermiscible (substantially oiland fat-free) liquid carrier made up of hydrophylic liquids having a high solvating action. A particularly suitable solvent carrier in this regard consists essentially of a combination of (A) from about 25 to about by weight, of ethyl alcohol or isopropyl alcohol, preferably the former, and (B) the balance essentially a liquid glycol above ethylene glycol or a liquid glycol above ethylene glycol and a liquid ethylene glycol mono methyl or mono ethyl ether. When the balance is essentially a combination of a liquid glycol and a liquid ethylene glycol mono ether, the former will usually predominate; that is to say, the liquid glycol will be present in an amount, by weight, greater than the liquid ethylene glycol mono ether.

Examples of suitable glycols are liquid polyethylene glycols, such as polyethylene glycol 400, propylene glycol and liquid polypropylene glycols. Of these the polyethylene glycols and propylene glycol are preferred. Examples of suitable liquid ethylene glycol ethers are the mono-, diand triethylene glycol monomethyl ethers and the mono-, diand triethylene glycol monoethyl ethers. Of these the monoand diethylene glycol monoethers are preferred. Small amounts of other materials which do not materially alter the advantageous characteristics of the composition may be included. For example, a small amount of polyethylene glycol 4000 may be included to thicken the composition. Likewise, a small amount of an antioxidant, like butylated hydroxytoluene, may be included as a stabilizer to increase shelf life.

Typical such solvent carriers are as follows (percent being by weight):

Percent Ethylene glycol monomethyl ether 25 Ethyl alcohol (95 25 Polyethylene glycol 400 50 Ethylene glycol monomethyl ether Ethyl alcohol (95%) 25 Polyethylene glycol 400 70 Ethylene glycol monoethyl ether 25 Ethyl alcohol (95%) 25 Polyethylene glycol 400 50 Diethylene glycol monoethyl ether 25 Ethyl alcohol (95%) 25 Polyethylene glycol 400 50 Ethy lalcohol (95%) 5O Propylene glycol 50 Ethyl alcohol (95%) 50 Polyethylene glycol 400 50 Isopropyl alcohol 50 Polyethylene glycol 400 50 Ethyl alcohol (95%) 50 Polypropylene glycol 400 50 As previously indicated, application of the vitamin A acid should be in such manner and in such concentration as to cause visible irritation. The concentration of the vitamin A acid in the topically-applied composition is generally in the order of about 0.1%, by weight, of the applied composition. Thus, the vitamin A acid concentration in the applied composition may range from 0.20% to 0.5%, by weight, with a concentration in the range of from about 0.05 to about 0.25% being preferred.

The vitamin A acid composition is applied daily until the desired relief is obtained, and this may require one or two (or possibly three) applications each day, depending upon the particular individual. Normally the treatment requires at least a month. Thus, acne in its mildest form (only a small number of comed'ones) may be substantially cleared in four to six weeks. However, more severe cases may require two to three months or longer.

On application there is an irritation to the skin, the patient feeling a tingling or irritating sensation which is caused by the vitamin A acid present. The irritation is readily observed by a flushing or diffuse reddening of the skin to which the vitamin A acid is applied followed by a peeling of the skin surface. It is important that the patient feel this irritation as this is indicative of the concentration needed to be eflective. Not only peeling, but, with inflammation, blackheads and whiteheads are converted into pustules followed by extrusion of the horny plug and healing of the lesions.

The vitamin A acid appears to have an effect substantially diiferent from the irritants generally employed. Its effect is twofold: it causes an intercellular edema of the epithelium lining the comedo which thereby becomes porous allowing products within the comedo to leak into the tissue. This incites the inflammation which converts the comedones. Secondly, it increases the rate of reproduction of epithelial cells so that the horny cells stream out more rapidly carrying the impaction with them. This is illustrated, for example, in the drawings wherein the several tfigures show the progressive stages of expulsion of the comedo, inflammatory in one case, increased keratinization in other. Not infrequently, new pustules and papules suddenly appear during the initial period of therapy. This has been found to be due to an inflammatory explosion of pre-existing comedones. Under the influence of the vitamin A acid, comedones, inert for Weeks or months, suddenly blow up. Since these inflammatory lesions are normally rather small, it is believed that the vitamin A acid excites inflammatory explosions at an earlier stage than could occur naturally. After this initial phase of exfoliation, the situation improves. If the treatment is to be ultimately effective on the particular individual there is usually an initial indication of the beginning of this effect at about the end of the third Week of treatment. Continued application of the vitamin A acid prevents the formation of new comedones and ameliorates the condition. When treatment is discontinued, however, comedones again develop since the present treatment does not reduce the amount of sebum or oil excreted by the skin.

Referring then to the figures, these are photornicrographs of exised specimens of skin. FIG. 1 shows an open comedo (blackhead) before treatment. FIG. 2 Shows the inflammatory reaction, caused by the present treatment, destroying epith'elia lining with consequent unseating of the comedo which will soon be exfoliated. FIG. 3 shows extrusion of the comedo as a result of speeding up of keratinization. Horny cells are being produced at an accelerated rate, and the comedo is being swept out by this stream of cells. FIG. 4 shows normal sebaceous follicles of the face. These follicles are the sites in which cornedones form. FIG. 5 shows the filling of the follicle with horny material, the intermediate stage of comedo formation.

The results of clinical tests on 103 patients using 0.1%, by weight, vitamin A acid in a clear vehicle consisting of equal parts of ethyl alcohol and propylene glycol are reported in Topical Vitamin A Acid in Acne Vulgaris, by Kligman, Fulton and Plewig in Arch. Derm., vol. 99, April 1969, pages 469476.

Having thus described my invention, I claim:

1. The method of treating acne comprising applying vitamin A acid topically to the aflected area in a concentration eflective for the treatment of acne and repeating such applications daily, whereby said applications result in the peeling and diffuse redness of the skin treated, and continuing said treatment until the acne has subsided.

2. The method of claim 1 comprising applying topically to the aifected area a composition comprising vitamin A acid and a carrier, and continuing said applications at spaced intervals of one to two times a day.

3. The method of claim 2 in which the concentration of vitamin A acid in the composition is in the order of about 0.1 percent, by weight, of the topically-applied composition.

4. The method of claim 2 in which the concentration of vitamin A acid in the composition is from 0.02 to 0.5 percent, by weight, of the topically applied composition.

5. The method of claim 2 in which the concentration of vitamin A acid in the composition is from 0.05 to 0.25 percent, by weight, of the topically applied composition.

6. The method of claim 2 wherein said carrier is a water-miscible organic liquid.

7. The method of claim 6 wherein said carrier consists essentially of (A) from about 25 to 75%, by weight, of an alcohol selected from the group consisting of ethyl and isopropyl, alcohol and 5 (B) the balance being essentially a liquid selected from the group consisting of (a) a liquid glycol above ethylene glycol, and (b) a mixture of a liquid glycol above ethylene glycol and a liquid lower alkyl ether of an ethylene glycol selected from the group consisting of the monomethyl and monoethyl ethers. 8. The method of claim 7 in which said alcohol is ethyl alcohol, said liquid glycol is a liquid polyethylene 10 glycol and said liquid ethylene glycol mono ether is selected from the group consisting of monoethylene glycol monomethyl ether, monoethylene glycol monoethyl ether, diethyleneglycol monomethyl ether and diethyleneglycol monoethyl ether.

9. The method of claim 8 in which said carrier consists essentially of. ethyl alcohol and liquid polyethylene glycol.

10. The method of claim 9 in which said ethyl alcohol and said polyethylene glycol are present in approximately equal parts by weight.

Refere ces Cited FOREIGN PATENTS 7/ 1962 Great Britain 424344 9/ 1962 Great Britain 424344 OTHER REFERENCES Beer: Dermatologica, vol. 124 (1962), pp. 192-195.

Stuttgen: Dermatologica, vol. 124 1962), pp. 78-79.

Flesch: American Perfume: and Cosmetics (July 1963), vol. 78, pp. 15-17.

Harry: Cosmetic Materials, 1st Edition (1950), pp. 113-1 15.

Mellan: Industrial Solvents, 2nd Edition (1950), pp. 448, 451, 463, 464, 544, 656-657.

ALBERT T. MEYERS, Primary Examiner N. A. DREZIN, Assistant Examiner U.S. C1. X.R.

Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US3882244 *21 Mar 19736 May 1975Univ CaliforniaMethod of treating acne with a c{hd 20 {b acid
US3906108 *12 Oct 197316 Sep 1975Johnson & JohnsonStabilized tretinoin cream emulsion
US3932665 *5 Abr 197413 Ene 1976Scott Eugene J VanProcess for the treatment of acne vulgaris utilizing retinal
US3934028 *22 Abr 197420 Ene 1976The Regents Of The University Of CaliforniaAcne and psoriasis treatment with retinoic acid analogs
US4021573 *5 Nov 19753 May 1977The Regents Of The University Of CaliforniaPsoriasis treatment with retinoic acid analogs
US4034114 *15 Sep 19765 Jul 1977Yu Ruey JTreatment of skin keratoses with retinal
US4055659 *3 Nov 197525 Oct 1977Johnson & JohnsonRetinoic acid derivatives
US4108880 *3 Nov 197522 Ago 1978Johnson & JohnsonEsters of retinoic acid
US4126697 *5 Ago 197721 Nov 1978Johnson & JohnsonRetinoic acid derivatives in the treatment of acne
US4170229 *16 Ene 19789 Oct 1979Dominion Pharmacal, Inc.Method for improved health care of hair and scalp using a vitamin A aqueous emulsion
US4190594 *15 May 197826 Feb 1980Johnson & JohnsonRetinoic acid derivatives
US4200647 *12 Dic 197829 Abr 1980Hoffmann-La Roche Inc.Retinoids
US4214000 *30 Oct 197822 Jul 1980Johnson & JohnsonZinc salt of all-trans-retinoic acid for the treatment of acne
US4239781 *3 May 197916 Dic 1980Roy EdwardsMethod for treating skin ailments
US4247547 *19 Mar 197927 Ene 1981Johnson & JohnsonTretinoin in a gel vehicle for acne treatment
US4603146 *26 Jul 198529 Jul 1986Kligman Albert MMethods for retarding the effects of aging of the skin
US4843096 *1 Dic 198627 Jun 1989Stiefel Laboratories, Inc.Nonaqueous gel of 13-cis-retinoic acid
US4877805 *3 Jun 198831 Oct 1989Kligman Albert MReversing collagen fiber loss by applying to face
US4889847 *3 Nov 198626 Dic 1989Ortho Pharmaceutical CorporationPrevention of glucocorticoid-induced skin atrophy
US4985235 *8 May 198915 Ene 1991Kligman Albert MTreatment of periodontoclasia with retinoic acid
US5019569 *31 Ago 198928 May 1991Ortho Pharmaceutical CorporationReversal of glucocorticoid-induced skin atrophy
US5051449 *27 Feb 199124 Sep 1991Kligman Albert MTreatment of cellulite with retinoids
US5124313 *2 Jun 198923 Jun 1992Schaeffer Hans AApplying extract of yellow or deep green vegetables which contains retinyl fatty acid ester complexed with polypeptide, isoprenoid
US5183817 *13 Dic 19882 Feb 1993Bazzano Gail SCombinations of retinoids and minoxidil-type compounds for hair growth
US5273739 *5 Nov 199228 Dic 1993Jim BaralComposition and treatment for darkening hair color
US5380764 *28 Ene 199310 Ene 1995Herzog; PaulSkin elasticity
US5459153 *10 Sep 199017 Oct 1995Leung; Lit-HungComposition and methods for treatment of acne vulgaris and for retardation of aging
US5514672 *13 Dic 19887 May 1996Bazzano; Gail S.Use of retinoids and compositions containing same for hair growth
US5643584 *18 May 19951 Jul 1997Ortho Pharmaceutical CorporationAqueous gel retinoid dosage form
US5661141 *27 Mar 199526 Ago 1997Petrow; Vladimir19-oxygenated steroids as therapeutic agents
US5670547 *26 Abr 199523 Sep 1997Dow Pharmaceutical SciencesMoisturizing vehicle for topical application of vitamin A acid
US5698593 *15 Abr 199316 Dic 1997The United States Of America As Represented By The Department Of Health And Human ServicesMethod for treating acne
US5721275 *7 Jun 199024 Feb 1998Bazzano; Gail S.Slow release vehicles for minimizing skin irritancy of topical compositions
US5998395 *10 Sep 19937 Dic 1999Kligman; Albert M.Methods of treating inflammatory dermatosis
US6008254 *1 May 199828 Dic 1999Kligman; Douglas E.Method of treating skin disorders with high-strength tretinoin
US6028105 *7 Jun 199522 Feb 2000Nigra; Thomas P.Topical drug delivery composition and method
US6063817 *19 Feb 199816 May 2000Bristol-Myers Squibb CompanyAntiischemic agents
US616911022 May 19972 Ene 2001Vivant PharmaceuticalsRejuvenating the skin using a combination of vitamin A and alphahydroxy acids
US62288879 May 20008 May 2001Douglas E. KligmanMethod of treating skin disorders with high-strength retinoids
US62386834 Dic 199829 May 2001Johnson & Johnson Consumer Companies, Inc.Drug delivery
US624876312 Oct 199919 Jun 2001Scivoletto RosemariePsoriasis
US634444811 Jul 19945 Feb 2002Stb Family Limited PartnershipComposition for the treatment of hair loss
US642921814 Nov 20006 Ago 2002Joseph ScivolettoApplying a serum, cream, or lotion containing extra niacin to treat skin disorders such as acne, blackheads, fine lines, and enlarged pores; concentration is sufficient to produce warmth, blush, flushing or redness of skin
US6586473 *12 Ene 20001 Jul 2003Medicis Pharmaceutical CorporationTopical drug delivery composition and method
US71794751 May 200020 Feb 2007Johnson & Johnson Consumer Companies, Inc.Anhydrous topical skin preparations
US76628559 Nov 200416 Feb 2010Imaginative Research Associates, Inc.For treatment of skin disorders (acne); solubilized in alcohol
US774948913 Dic 20066 Jul 2010Celmatrix CorporationTopical administration carrier composition and therapeutic formulations comprising same
US81191116 Jul 201021 Feb 2012Celmatrix CorporationTopical administration carrier composition and therapeutic formulations comprising same
US814781516 Dic 20053 Abr 2012Celmatrix CorporationTopical administration carrier composition and therapeutic formulations comprising same
US823227626 Nov 200331 Jul 2012Johnson & Johnson Comsumer Companies, Inc.Anhydrous topical skin preparations
US829912214 Abr 200930 Oct 2012Skinvisible Pharmaceuticals, Inc.Method for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition
US844496021 Feb 201221 May 2013Celmatrix CorporationTopical administration carrier composition and therapeutic formulations comprising same
USRE36068 *2 Abr 199626 Ene 1999Kligman; Albert M.Treating skin with retinoic acid derivatives
USRE411347 Jun 199916 Feb 2010Alyzan, Inc.Slow release vehicles for minimizing skin irritancy of topical compositions
DE2601489A1 *16 Ene 197622 Jul 1976Johnson & JohnsonTretinoin enthaltende gelpraeparate
EP0699439A210 Ago 19956 Mar 1996Pfizer Inc.Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
EP1159956A2 *30 Abr 20015 Dic 2001Johnson & Johnson Consumer Companies, Inc.Anhydrous topical skin preparations
EP1645287A2 *3 Dic 199912 Abr 2006Johnson and Johnson Consumer Companies, Inc.Anhydrous topical skin preparations
EP1714640A1 *13 Jul 199325 Oct 2006Shiseido Company, Ltd.Stabilised external skin treatment composition comprising retinol.
WO1990014833A1 *7 Jun 19908 Dic 1990Gail S BazzanoSlow release vehicles for minimizing skin irritancy of topical compositions
WO1992015293A126 Feb 199228 Ago 1992Albert M KligmanTreatment of cellulite with retinoids
WO1993006086A1 *10 Ago 19921 Abr 1993PfizerRetinoids and their use in treating skin diseases and leukemia
WO1998050023A1 *11 May 199812 Nov 1998Kligman Albert MUse of high dose retinoids for the treatment of skin disorders
WO2000033877A1 *3 Dic 199915 Jun 2000Johnson & Johnson ConsumerAnhydrous topical skin preparations
Clasificación de EE.UU.514/559
Clasificación internacionalC07C57/00, A61K8/30, A61K47/10, A61K8/67, A61Q19/00, C07C57/26, A61K9/00
Clasificación cooperativaA61Q19/00, A61K8/671, A61K47/10, C07C57/26, A61K9/0014
Clasificación europeaA61K47/10, A61Q19/00, C07C57/26, A61K9/00M3, A61K8/67C